Engineering of NK activating receptor ligands enhances immune compatibility of MHC-Iâ/â iPSC-derived β cells for cell therapy of type 1 diabetes
Chimienti, R., Baccega, T., Manenti, F., Torchio, S., Pellegrini, S., Cospito, A., Monti, P., Sordi, V., Lombardo, A., Malnati, M., Piemonti, L.Volume:
22
Journal:
Cytotherapy
DOI:
10.1016/j.jcyt.2020.03.479
Date:
May, 2020
File:
PDF, 205 KB
2020